| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
37,975 | 38,586 | 46,305 | 29,356 | 11,352 | 38 | |
General and administrative | ||||||
10,879 | 10,636 | 10,219 | 7,620 | 2,418 | 123 | |
Total operating expenses | ||||||
- | - | - | - | - | 161 | |
Total operating expenses | ||||||
48,854 | 49,222 | 56,524 | 36,976 | 13,770 | - | |
Loss from operations | ||||||
-48,854 | -49,222 | -56,524 | -36,976 | -13,770 | -161 | |
Change in fair value of convertible preferred stock liability | ||||||
- | - | - | - | 17,600 | - | |
Interest income and other expense, net | ||||||
2,182 | 2,283 | 861 | 601 | 35 | - | |
Net loss | ||||||
-46,672 | -46,939 | -55,663 | -36,375 | -31,335 | -161 | |
Net loss per share, basic and diluted (in dollars per share) | ||||||
-1.59 | -1.71 | -2.72 | -2.36 | -83.86 | -0.95 | |
Shares used to compute net loss per share, basic and diluted (in shares) | ||||||
29,349 | 27,509 | 20,488 | 15,422 | 373 | 170 | |
Shares used to compute pro forma net loss per share, diluted (in shares) | ||||||
- | - | - | 15,422 | - | - | |
Other comprehensive loss: | ||||||
Unrealized gain on marketable securities | ||||||
63 | 7 | -2 | 6 | -45 | - | |
Comprehensive loss | ||||||
-46,609 | -46,932 | -55,665 | -36,369 | -31,380 | -161 | |